PT - JOURNAL ARTICLE AU - de Oliveira, Jarbas Maciel AU - Zurro, Nuria Bengala AU - Campos Coelho, Antonio Victor AU - Caraciolo, Marcel Pinheiro AU - de Alexandre, Rodrigo Bertollo AU - Carvalho Neto, George de Vasconcelos AU - Grivicich, Ivana AU - de Oliveira Filho, João Bosco TI - Frequency of variants of hereditary cancer risk syndrome in 1682 Brazilian patients genotyped by next-generation sequencing AID - 10.1101/2021.04.15.21255554 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.15.21255554 4099 - http://medrxiv.org/content/early/2021/04/20/2021.04.15.21255554.short 4100 - http://medrxiv.org/content/early/2021/04/20/2021.04.15.21255554.full AB - Hereditary cancer risk syndromes are a group of disorders caused by germline variants in a growing number of genes. Most studies on hereditary cancer have been conducted in white populations. Here we report the largest study in Brazilian individuals with multiple, self-reported, ethnicities. We genotyped 1682 individuals from all regions of the country who were referred to genetic testing for hereditary cancer risk with multigene Next-generation sequencing (NGS) panels. Most were women, and had a personal and/or family history of cancer. The majority of cancer cases were breast and ovarian. We identified a total of 321 pathogenic/likely pathogenic (P/LP) variants in 305 people (18.1%), corresponding to 166 unique variants. These variants were distributed among 32 genes, and most were detected on BRCA1 and BRCA2 (129 patients, 26.2% and 14.3% of all P/LP hits, respectively). The prevalence of any genes transheterozygosity in our sample was 0.89% (15/1682). The BRCA1/BRCA2 double heterozygosity rate was 0.78% (1/129) for BRCA variants carriers and 0.06% (1/1682) overall. We classified patients according to the NCCN and Brazilian National Health Agency (ANS) genetic testing recommendation criteria. We found that the criteria had false negative rates of 17.3% and 44.2%, meaning that both failed to detect a substantial part of P/LP positive patients. Therefore, our results show that NGS adds to knowledge on the Brazilian spectrum of germline variants associated with cancer risk and indicate that Brazilian testing guidelines should be improved.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was approved by the Institutional review board from the Research Ethics Committee of the Institute of Integral Medicine Professor Fernando Figueira (CEP-IMIP) in Recife, Pernambuco and all individuals provided written consent for multi-gene testing (protocol number CAAE 29567220.4.1001.0071).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available within the article or its supplementary materials.